Maltodextrin: A novel excipient used in sugar-based orally disintegrating tablets and phase transition process

AAPS PharmSciTech

Volumn 11, Issue 2, 2010, Pages 645-651

  Elnaggar, Yosra Shaaban R ^a   El Massik, Magda A ^a   Abdallah, Ossama Y ^a   Ebian, Abd Elazim R ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Disintegration time; Maltodextrin; Meclizine; Orally disintegrating tablets; Phase transition

Indexed keywords

EXCIPIENT; MALTODEXTRIN; MECLOZINE; CARBOHYDRATE; DELAYED RELEASE FORMULATION; POLYSACCHARIDE; TABLET;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DEGRADATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PHASE TRANSITION; PRIORITY JOURNAL; TABLET DISINTEGRATION; TABLET HARDNESS; X RAY ANALYSIS; X RAY DIFFRACTION; ADMINISTRATION AND DOSAGE; CHEMISTRY; COMPRESSIVE STRENGTH; DELAYED RELEASE FORMULATION; DRUG FORMULATION; DRUG STABILITY; HARDNESS; ORAL DRUG ADMINISTRATION; PROCEDURES; SYNTHESIS; TABLET;

ADMINISTRATION, ORAL; CARBOHYDRATES; COMPRESSIVE STRENGTH; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; HARDNESS; PHASE TRANSITION; POLYSACCHARIDES; TABLETS;

EID: 77954815987     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9423-y     Document Type: Article

References (25)

1. Armando YP, Schramm SG, Silva M, Kano EK, Koono E E M, Porta V et al. Bioequivalence assay between orally disintegrating and conventional tablet formulations in healthy volunteers. Int J Pharm. 2009;336:149-53.
2. Chandrasekhar R, Hassan Z, Alhusban F, Smith AM, Mohammed AR. The role of formulation excipients in the development of lyophilised fast disintegrating tablets. Eur J Pharm Biopharm. 2009;72:119-29.
3. Kuno Y, Kojima M, Nakagami H, Yonemochi E, Terada K. Effect of the type of lubricant on the characteristics of orally disintegrating tablets manufactured using the phase transition of sugar alcohol. Eur J Pharm Biopharm. 2008;69:986-92.
4. Xu J, Bovet LL, Zhao K. Taste masking microspheres for orally disintegrating tablets. Int J Pharm. 2008;359:63-9.
5. Jain RA, Brito L, Straub JA, Tessier T, Bernstein H. Effect of powder processing on performance of fenofibrate formulations. Eur J Pharm Biopharm. 2008;69:727-34.
6. Fini A, Bergamante V, Ceschel GC, Ronchi C, Fonseca CA. Fast dispersible/slow releasing ibuprofen tablets. Eur J Pharm Biopharm. 2008;69:335-41.
7. Breitkreutz J. European perspectives on pediatric formulations. Clin Therap. 2008;30:2146-54.
8. Factor SA. Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics. 2008;5:164-80.
9. Lader M. Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target. Eur Neuropsychopharmacology. 2007;17:743-55.
10. Panigrahi D, Baghel S, Mishra B. Mouth dissolving tablets: an overview of preparation techniques, evaluation and patented technologies. J Pharm Research. 2005;4:33-8.
11. Parakh SR, Gothoskar AV. A review of mouth dissolving tablet technologies. Pharm Tech. 2003;27:92-100.
12. Kuno Y, Kojima M, Ando S, Nakagami H. Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols. J Contr Release. 2005;105:16-22.
13. Mizumoto T, Yoshinori M, Yamamoto T, Yonemochi E, Katsuhide T. Formulation of novel fast-disintegrating tablets. Int J Pharm. 2005;306:83-90.
14. Sugimoto M, Maejima T, Narisawa S, Matsubara K, Yoshino H. Factors affecting the characteristics of rapidly disintegrating tablets in the mouth prepared by the crystalline transition of amorphous sucrose. Int J Pharm. 2005;296:64-72.
15. Corveleyn S, Remon JP. Formulation and production of rapidly disintegrating tablets by lyophilization using hydrochlorothiazide as a model drug. Int J Pharm. 1997;152:215-25.
16. Moffat AC, Osselton MD, Widdop B. Clarke's analysis of drugs and poisons. 3rd ed. London: Pharmaceutical; 2004.
17. Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, Iida K. Preparation and evaluation of compressed tablets rapidly disintegrating in oral cavity. Chem Pharm Bull. 1996;44:2121-7.
18. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Orally Disintegrating Tablets. 2007 http://www.fda.gov/cder/guidance/ index.htm. Accessed 16 June 2007.
19. Papadimitriou E, Efentakis M, Choulis NH. Evaluation of maltodextrins as excipients for direct compression tablets and their influence on the rate of dissolution. Int J Pharm. 1992;86:131-6.
20. Labuza T. Literature review on: water activity and glass transition. University of Minnesota, Department of food science and nutrition. 2007. http://www.faculty.che.umn.edu. Accessed 15 April 2007.
21. Sperling LH. Introduction to physical polymer science. New York: Wiley; 1986. p. 224-95.
22. Ferry JD. Viscoelastic properties of polymers. New York: Wiley; 1980. p. 264-320.
23. Roozen MJ, Hemminga MA, Walstra P. Molecular motion in glassy water maltooligosaccharide (maltodexrtin) mixtures as studied by conventional and saturation-transfer spin-probe spectroscopy. Carbohydr Res. 1991;215:229-37.
24. Yunxia B, Yorinobu Y, Hisakazu S. Rapidly disintegrating tablets prepared by the wet compression method: mechanism and optimization. J Pharm Sci. 1999;88:1004-10.
25. Li LC, Peck GE. The effect of moisture content on the compression properties of maltodextrins. J Pharm Pharmacol. 1990;42:272-5.